Clinical outcome of beta3 agonists, Mirabegron and Vibegron sequential therapy for overactive bladder(OAB)

Clinical outcome of beta3 agonists, Mirabegron and Vibegron sequential therapy for overactive bladder(OAB) - OAB beta3 agonists sequential therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038636

Enrollment

100

Registered

2019-12-01

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive bladder

Interventions

Initially treated with 50mg Mirabegron for 2months and switched to 50mg Vibegron for 2months Initially treated with 50mg Vibegron for 2months and switched to 50mg Mirabegron for 2months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who fit the following criteria 1) chief complaint is urinary urgency 2) OABSS total score is more than 3 and Q3 is more than 2 3) accepted with written consent

Exclusion criteria

Exclusion criteria: 1) Urgency due to bladder infection,urinary malignancies 2) patients who is not available for beta3 agonist treatment 3) deny attending this clinical research

Design outcomes

Primary

Measure	Time frame
change of OABSS after 8 week initial beta3 agonist therapy and change of OABSS after 8 week beta3 agonist sequential therapy	—

Countries

Japan

Contacts

Public ContactShunsuke Tsuzuki

Jikei University school of medicine Department of Urology

tsuzushun60@gmail.com03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026